Blueprint Medicines Corporation (BPMC) EPS Estimated At $-1.55

October 2, 2018 - By Ellis Scott

Blueprint Medicines Corporation (NASDAQ:BPMC) Logo

Analysts expect Blueprint Medicines Corporation (NASDAQ:BPMC) to report $-1.55 EPS on October, 30.They anticipate $0.59 EPS change or 61.46 % from last quarter’s $-0.96 EPS. After having $-0.62 EPS previously, Blueprint Medicines Corporation’s analysts see 150.00 % EPS growth. The stock decreased 2.66% or $1.965 during the last trading session, reaching $71.925. About 20,117 shares traded. Blueprint Medicines Corporation (NASDAQ:BPMC) has risen 54.64% since October 2, 2017 and is uptrending. It has outperformed by 39.02% the S&P500.

Blueprint Medicines Corporation (NASDAQ:BPMC) Ratings Coverage

Among 5 analysts covering Blueprint Medicines (NASDAQ:BPMC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicines had 7 analyst reports since April 16, 2018 according to SRatingsIntel. JMP Securities maintained the shares of BPMC in report on Monday, June 4 with “Market Outperform” rating. The company was maintained on Monday, April 16 by JMP Securities. Canaccord Genuity maintained it with “Buy” rating and $10500 target in Thursday, May 3 report. The rating was maintained by BTIG Research with “Buy” on Wednesday, May 2. The stock has “Buy” rating by Wedbush on Monday, April 16. The stock has “Buy” rating by Canaccord Genuity on Monday, April 16.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. The company has market cap of $3.16 billion. The Company’s lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It currently has negative earnings. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase and predicted NTRK resistant mutants.

Another recent and important Blueprint Medicines Corporation (NASDAQ:BPMC) news was published by which published an article titled: “Blueprint Medicines’ BLU-667 shows encouraging action treatment-resistant lung cancer” on September 26, 2018.

Blueprint Medicines Corporation (NASDAQ:BPMC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: